FDA approves new therapy for Dravet syndrome
SILVER SPRING, Md. — The U.S. Food and Drug Administration approved on Friday Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting seizures despite
